| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hyperlipoproteinemia Type II | 158 | 2021 | 395 | 40.570 |
Why?
|
| Lipoprotein(a) | 44 | 2021 | 479 | 9.950 |
Why?
|
| Dyslipidemias | 55 | 2021 | 868 | 9.640 |
Why?
|
| Cholesterol, LDL | 104 | 2021 | 2379 | 8.980 |
Why?
|
| Anticholesteremic Agents | 65 | 2021 | 967 | 8.930 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 101 | 2021 | 3244 | 7.760 |
Why?
|
| Hypolipidemic Agents | 47 | 2021 | 609 | 7.230 |
Why?
|
| Lipoproteins | 52 | 2020 | 879 | 5.280 |
Why?
|
| Hypertriglyceridemia | 16 | 2021 | 293 | 4.550 |
Why?
|
| Apolipoprotein B-100 | 34 | 2019 | 157 | 4.330 |
Why?
|
| Atherosclerosis | 48 | 2021 | 3400 | 4.320 |
Why?
|
| Cardiovascular Diseases | 96 | 2021 | 15498 | 4.080 |
Why?
|
| Apolipoproteins B | 41 | 2021 | 385 | 3.800 |
Why?
|
| Hyperlipidemias | 21 | 2021 | 770 | 3.240 |
Why?
|
| Blood Component Removal | 17 | 2020 | 132 | 3.190 |
Why?
|
| Triglycerides | 55 | 2021 | 2459 | 3.180 |
Why?
|
| Proprotein Convertases | 14 | 2018 | 95 | 3.140 |
Why?
|
| Cholesterol | 50 | 2021 | 2903 | 3.100 |
Why?
|
| Fenofibrate | 19 | 2018 | 87 | 2.920 |
Why?
|
| Hypercholesterolemia | 20 | 2020 | 1141 | 2.810 |
Why?
|
| Postprandial Period | 15 | 2019 | 314 | 2.780 |
Why?
|
| Coronary Artery Disease | 37 | 2021 | 6403 | 2.620 |
Why?
|
| Antibodies, Monoclonal | 25 | 2021 | 9172 | 2.570 |
Why?
|
| Lipid Metabolism | 26 | 2021 | 1896 | 2.520 |
Why?
|
| Genetic Testing | 30 | 2020 | 3533 | 2.510 |
Why?
|
| Australia | 42 | 2021 | 1248 | 2.460 |
Why?
|
| Lipoproteins, VLDL | 25 | 2018 | 201 | 2.370 |
Why?
|
| General Practice | 8 | 2021 | 95 | 2.340 |
Why?
|
| Receptors, LDL | 21 | 2020 | 488 | 2.330 |
Why?
|
| Apolipoprotein B-48 | 14 | 2018 | 20 | 2.200 |
Why?
|
| Cholesterol, HDL | 34 | 2021 | 1810 | 2.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 46 | 2021 | 12142 | 2.110 |
Why?
|
| Ubiquinone | 10 | 2018 | 183 | 2.030 |
Why?
|
| Lipoproteins, LDL | 16 | 2019 | 642 | 1.890 |
Why?
|
| Apolipoprotein C-III | 19 | 2018 | 210 | 1.870 |
Why?
|
| Lipids | 32 | 2021 | 3332 | 1.730 |
Why?
|
| Diabetic Angiopathies | 10 | 2014 | 803 | 1.700 |
Why?
|
| Endothelium, Vascular | 27 | 2015 | 4433 | 1.690 |
Why?
|
| Mass Screening | 21 | 2020 | 5424 | 1.670 |
Why?
|
| Fatty Acids, Omega-3 | 16 | 2019 | 1390 | 1.640 |
Why?
|
| Humans | 506 | 2021 | 760617 | 1.620 |
Why?
|
| Apolipoprotein A-II | 11 | 2016 | 41 | 1.610 |
Why?
|
| Brachial Artery | 17 | 2018 | 366 | 1.580 |
Why?
|
| Fatty Liver | 9 | 2014 | 787 | 1.570 |
Why?
|
| Serine Endopeptidases | 12 | 2015 | 1022 | 1.560 |
Why?
|
| Risk Reduction Behavior | 10 | 2018 | 1110 | 1.460 |
Why?
|
| Insulin Resistance | 34 | 2017 | 3954 | 1.430 |
Why?
|
| Lipoproteins, HDL | 20 | 2016 | 675 | 1.410 |
Why?
|
| Western Australia | 19 | 2020 | 41 | 1.390 |
Why?
|
| Primary Health Care | 11 | 2020 | 4668 | 1.350 |
Why?
|
| Cardiology | 8 | 2021 | 1656 | 1.320 |
Why?
|
| Coronary Disease | 18 | 2021 | 5912 | 1.320 |
Why?
|
| Dietary Supplements | 20 | 2019 | 3411 | 1.250 |
Why?
|
| Risk Factors | 111 | 2021 | 74115 | 1.230 |
Why?
|
| Hyperlipoproteinemias | 4 | 2019 | 20 | 1.230 |
Why?
|
| Apoprotein(a) | 4 | 2020 | 17 | 1.200 |
Why?
|
| Lipid Regulating Agents | 2 | 2019 | 21 | 1.180 |
Why?
|
| Intention | 3 | 2019 | 346 | 1.150 |
Why?
|
| General Practitioners | 5 | 2016 | 90 | 1.140 |
Why?
|
| Heptanoic Acids | 14 | 2015 | 344 | 1.130 |
Why?
|
| Early Diagnosis | 15 | 2018 | 1185 | 1.130 |
Why?
|
| Kinetics | 39 | 2019 | 6370 | 1.110 |
Why?
|
| Fluorobenzenes | 8 | 2015 | 179 | 1.100 |
Why?
|
| Hyperlipidemia, Familial Combined | 2 | 2016 | 14 | 1.090 |
Why?
|
| Apolipoprotein A-I | 16 | 2013 | 299 | 1.070 |
Why?
|
| Health Knowledge, Attitudes, Practice | 9 | 2021 | 4007 | 1.060 |
Why?
|
| Muscular Diseases | 5 | 2019 | 553 | 1.020 |
Why?
|
| Coronary Care Units | 3 | 2020 | 235 | 1.020 |
Why?
|
| Middle Aged | 207 | 2021 | 220584 | 1.020 |
Why?
|
| Serine Proteinase Inhibitors | 4 | 2019 | 175 | 1.010 |
Why?
|
| Eicosapentaenoic Acid | 8 | 2019 | 561 | 0.980 |
Why?
|
| Male | 244 | 2021 | 360358 | 0.980 |
Why?
|
| Obesity | 36 | 2020 | 12933 | 0.970 |
Why?
|
| Azetidines | 5 | 2015 | 142 | 0.970 |
Why?
|
| Vasodilation | 13 | 2018 | 962 | 0.940 |
Why?
|
| Adiponectin | 11 | 2015 | 1107 | 0.930 |
Why?
|
| Blood Chemical Analysis | 6 | 2019 | 436 | 0.910 |
Why?
|
| Diet Therapy | 4 | 2019 | 151 | 0.890 |
Why?
|
| Forearm | 8 | 2010 | 427 | 0.870 |
Why?
|
| Oligonucleotides | 4 | 2021 | 566 | 0.860 |
Why?
|
| Adult | 162 | 2021 | 220969 | 0.850 |
Why?
|
| Pyrroles | 14 | 2015 | 1125 | 0.840 |
Why?
|
| Arteries | 8 | 2011 | 1122 | 0.830 |
Why?
|
| Cost-Benefit Analysis | 15 | 2021 | 5491 | 0.810 |
Why?
|
| Drug Therapy | 2 | 2016 | 503 | 0.810 |
Why?
|
| Carotid Artery Diseases | 6 | 2018 | 877 | 0.810 |
Why?
|
| Chylomicrons | 5 | 2010 | 26 | 0.790 |
Why?
|
| Self Care | 2 | 2018 | 796 | 0.790 |
Why?
|
| Female | 189 | 2021 | 392148 | 0.780 |
Why?
|
| Diet, Reducing | 5 | 2014 | 485 | 0.770 |
Why?
|
| Consensus | 14 | 2020 | 3117 | 0.760 |
Why?
|
| Polycystic Ovary Syndrome | 8 | 2014 | 376 | 0.760 |
Why?
|
| Cholesterol, VLDL | 9 | 2016 | 70 | 0.750 |
Why?
|
| Berberine | 2 | 2020 | 26 | 0.750 |
Why?
|
| Education, Medical, Continuing | 3 | 2018 | 823 | 0.750 |
Why?
|
| International Cooperation | 5 | 2018 | 1421 | 0.740 |
Why?
|
| Delivery of Health Care | 6 | 2020 | 5332 | 0.740 |
Why?
|
| Disease Management | 5 | 2020 | 2506 | 0.730 |
Why?
|
| Niacin | 5 | 2019 | 118 | 0.730 |
Why?
|
| Isotope Labeling | 8 | 2014 | 392 | 0.730 |
Why?
|
| Nutritional Physiological Phenomena | 3 | 2008 | 361 | 0.720 |
Why?
|
| Dicarboxylic Acids | 1 | 2021 | 77 | 0.720 |
Why?
|
| Obesity, Abdominal | 9 | 2016 | 373 | 0.720 |
Why?
|
| Internationality | 6 | 2019 | 1000 | 0.710 |
Why?
|
| Renal Insufficiency, Chronic | 12 | 2019 | 2249 | 0.710 |
Why?
|
| Apolipoproteins A | 4 | 2019 | 95 | 0.700 |
Why?
|
| Natural Killer T-Cells | 9 | 2019 | 322 | 0.690 |
Why?
|
| Medication Therapy Management | 2 | 2020 | 130 | 0.690 |
Why?
|
| Sulfonamides | 9 | 2015 | 1977 | 0.690 |
Why?
|
| Registries | 13 | 2020 | 8207 | 0.690 |
Why?
|
| Patient Care | 2 | 2017 | 621 | 0.680 |
Why?
|
| Phenotype | 23 | 2021 | 16571 | 0.680 |
Why?
|
| Carrier Proteins | 8 | 2016 | 4935 | 0.680 |
Why?
|
| Risk Assessment | 35 | 2020 | 23972 | 0.660 |
Why?
|
| Probucol | 5 | 2020 | 25 | 0.660 |
Why?
|
| Synovial Membrane | 9 | 2020 | 532 | 0.660 |
Why?
|
| Aged | 109 | 2021 | 169042 | 0.650 |
Why?
|
| Life Style | 11 | 2017 | 3904 | 0.650 |
Why?
|
| Mutation | 28 | 2020 | 30016 | 0.630 |
Why?
|
| Blood Pressure | 22 | 2019 | 8472 | 0.630 |
Why?
|
| Liver | 19 | 2017 | 7512 | 0.630 |
Why?
|
| Family Health | 5 | 2016 | 1253 | 0.630 |
Why?
|
| Peripheral Arterial Disease | 2 | 2020 | 1271 | 0.620 |
Why?
|
| Fatty Acids, Nonesterified | 7 | 2016 | 393 | 0.610 |
Why?
|
| Vasodilator Agents | 7 | 2015 | 973 | 0.610 |
Why?
|
| Benzimidazoles | 4 | 2016 | 858 | 0.600 |
Why?
|
| Practice Guidelines as Topic | 16 | 2020 | 7389 | 0.600 |
Why?
|
| Drug Therapy, Combination | 21 | 2019 | 6305 | 0.600 |
Why?
|
| Fatty Acids | 6 | 2021 | 1808 | 0.600 |
Why?
|
| Double-Blind Method | 39 | 2021 | 12334 | 0.600 |
Why?
|
| Models, Biological | 16 | 2017 | 9461 | 0.590 |
Why?
|
| Fibroblasts | 12 | 2020 | 4137 | 0.590 |
Why?
|
| Vascular Diseases | 5 | 2016 | 1160 | 0.580 |
Why?
|
| Genetic Predisposition to Disease | 24 | 2021 | 17878 | 0.580 |
Why?
|
| Plaque, Atherosclerotic | 6 | 2020 | 1532 | 0.580 |
Why?
|
| Physicians, Primary Care | 3 | 2021 | 617 | 0.580 |
Why?
|
| Diet | 13 | 2017 | 8048 | 0.570 |
Why?
|
| Carotid Arteries | 5 | 2018 | 941 | 0.550 |
Why?
|
| Cholestyramine Resin | 1 | 2016 | 25 | 0.550 |
Why?
|
| Psychotic Disorders | 12 | 2020 | 3220 | 0.550 |
Why?
|
| Pyrimidines | 8 | 2015 | 3027 | 0.530 |
Why?
|
| Clinical Trials as Topic | 12 | 2019 | 7995 | 0.530 |
Why?
|
| Preventive Health Services | 2 | 2019 | 566 | 0.510 |
Why?
|
| Prevalence | 25 | 2021 | 15689 | 0.500 |
Why?
|
| Drugs, Investigational | 1 | 2017 | 212 | 0.500 |
Why?
|
| Abetalipoproteinemia | 1 | 2015 | 16 | 0.500 |
Why?
|
| Adolescent | 47 | 2021 | 88234 | 0.490 |
Why?
|
| Telomere | 2 | 2018 | 940 | 0.490 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2019 | 604 | 0.480 |
Why?
|
| Homeostasis | 12 | 2017 | 3321 | 0.480 |
Why?
|
| Predictive Value of Tests | 25 | 2021 | 15251 | 0.480 |
Why?
|
| Niemann-Pick Disease, Type B | 1 | 2014 | 7 | 0.470 |
Why?
|
| Homozygote | 11 | 2019 | 1776 | 0.460 |
Why?
|
| Acute Coronary Syndrome | 3 | 2017 | 2190 | 0.460 |
Why?
|
| Heterozygote | 14 | 2019 | 2780 | 0.460 |
Why?
|
| Models, Cardiovascular | 1 | 2019 | 981 | 0.460 |
Why?
|
| Treatment Outcome | 50 | 2021 | 64568 | 0.460 |
Why?
|
| Medication Adherence | 5 | 2021 | 2174 | 0.450 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 1 | 2014 | 61 | 0.450 |
Why?
|
| Sphingomyelin Phosphodiesterase | 1 | 2014 | 82 | 0.450 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 12 | 2015 | 353 | 0.440 |
Why?
|
| Young Adult | 41 | 2020 | 59179 | 0.440 |
Why?
|
| Hypertension | 13 | 2021 | 8529 | 0.440 |
Why?
|
| Foundations | 1 | 2013 | 95 | 0.440 |
Why?
|
| Adipose Tissue | 9 | 2015 | 3309 | 0.440 |
Why?
|
| Forecasting | 4 | 2018 | 2924 | 0.440 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2018 | 940 | 0.430 |
Why?
|
| Glucagon-Like Peptide 2 | 1 | 2013 | 45 | 0.430 |
Why?
|
| Cross-Over Studies | 19 | 2018 | 2079 | 0.430 |
Why?
|
| Animals | 62 | 2020 | 168201 | 0.430 |
Why?
|
| Immunization | 1 | 2017 | 1217 | 0.420 |
Why?
|
| Lipid Metabolism, Inborn Errors | 1 | 2013 | 123 | 0.420 |
Why?
|
| Fasting | 5 | 2016 | 1603 | 0.420 |
Why?
|
| Models, Theoretical | 2 | 2016 | 3567 | 0.420 |
Why?
|
| Steroid Metabolism, Inborn Errors | 1 | 2012 | 5 | 0.420 |
Why?
|
| Arthritis, Rheumatoid | 11 | 2020 | 3752 | 0.410 |
Why?
|
| Cholinergic Antagonists | 1 | 2013 | 167 | 0.410 |
Why?
|
| Health Literacy | 1 | 2018 | 443 | 0.410 |
Why?
|
| DNA Mutational Analysis | 7 | 2019 | 4110 | 0.410 |
Why?
|
| Cross-Sectional Studies | 25 | 2021 | 26049 | 0.400 |
Why?
|
| Apolipoproteins | 8 | 2014 | 326 | 0.400 |
Why?
|
| Weight Loss | 9 | 2014 | 2682 | 0.400 |
Why?
|
| Hepatocytes | 2 | 2017 | 1231 | 0.400 |
Why?
|
| Malaysia | 4 | 2021 | 107 | 0.380 |
Why?
|
| Simvastatin | 2 | 2015 | 346 | 0.380 |
Why?
|
| Secondary Prevention | 6 | 2021 | 1469 | 0.380 |
Why?
|
| Coronary Stenosis | 2 | 2018 | 794 | 0.370 |
Why?
|
| Vascular Surgical Procedures | 1 | 2020 | 1489 | 0.370 |
Why?
|
| Safety | 1 | 2016 | 1149 | 0.370 |
Why?
|
| Vascular Resistance | 6 | 2016 | 930 | 0.370 |
Why?
|
| Cadherins | 5 | 2019 | 901 | 0.360 |
Why?
|
| Herpesvirus 2, Human | 1 | 2012 | 191 | 0.360 |
Why?
|
| Diabetes Complications | 2 | 2020 | 1315 | 0.360 |
Why?
|
| Diet, Fat-Restricted | 3 | 2010 | 329 | 0.360 |
Why?
|
| Child | 30 | 2021 | 80079 | 0.350 |
Why?
|
| Australasia | 4 | 2017 | 21 | 0.350 |
Why?
|
| Pravastatin | 3 | 2017 | 392 | 0.350 |
Why?
|
| Patient Participation | 1 | 2019 | 1443 | 0.350 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2013 | 364 | 0.350 |
Why?
|
| Phytosterols | 5 | 2010 | 55 | 0.350 |
Why?
|
| Morbidity | 4 | 2020 | 1750 | 0.350 |
Why?
|
| Physicians | 2 | 2021 | 4583 | 0.340 |
Why?
|
| Genotype | 7 | 2020 | 12978 | 0.340 |
Why?
|
| Pharmacists | 1 | 2012 | 258 | 0.340 |
Why?
|
| Docosahexaenoic Acids | 6 | 2016 | 907 | 0.340 |
Why?
|
| Benzodiazepines | 1 | 2016 | 1132 | 0.330 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 1418 | 0.330 |
Why?
|
| Sterol O-Acyltransferase | 1 | 2009 | 28 | 0.330 |
Why?
|
| Cost of Illness | 4 | 2020 | 1935 | 0.330 |
Why?
|
| Renal Insufficiency | 1 | 2015 | 808 | 0.330 |
Why?
|
| Genetic Markers | 5 | 2018 | 2601 | 0.330 |
Why?
|
| Energy Metabolism | 2 | 2020 | 2878 | 0.330 |
Why?
|
| Professional Role | 1 | 2012 | 313 | 0.330 |
Why?
|
| Phospholipid Transfer Proteins | 2 | 2006 | 90 | 0.320 |
Why?
|
| Standard of Care | 1 | 2012 | 551 | 0.320 |
Why?
|
| Herpes Simplex | 1 | 2012 | 465 | 0.310 |
Why?
|
| Muscle, Skeletal | 3 | 2019 | 4947 | 0.310 |
Why?
|
| Endothelium | 1 | 2011 | 764 | 0.310 |
Why?
|
| Capsules | 3 | 2020 | 191 | 0.310 |
Why?
|
| Combined Modality Therapy | 8 | 2020 | 8516 | 0.310 |
Why?
|
| Vulnerable Populations | 1 | 2014 | 704 | 0.310 |
Why?
|
| Oxidative Stress | 5 | 2016 | 3113 | 0.310 |
Why?
|
| Pedigree | 9 | 2019 | 4539 | 0.310 |
Why?
|
| Blood Glucose | 14 | 2020 | 6390 | 0.300 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2019 | 3415 | 0.300 |
Why?
|
| Metabolism | 2 | 2015 | 193 | 0.300 |
Why?
|
| Incidence | 9 | 2020 | 21337 | 0.300 |
Why?
|
| Myocardial Infarction | 6 | 2021 | 11459 | 0.300 |
Why?
|
| Randomized Controlled Trials as Topic | 17 | 2020 | 10199 | 0.300 |
Why?
|
| Patient Admission | 1 | 2015 | 1365 | 0.300 |
Why?
|
| Congenital Abnormalities | 1 | 2012 | 709 | 0.290 |
Why?
|
| Gemfibrozil | 1 | 2007 | 30 | 0.290 |
Why?
|
| Impotence, Vasculogenic | 1 | 2007 | 12 | 0.290 |
Why?
|
| Algorithms | 7 | 2019 | 14018 | 0.290 |
Why?
|
| Starvation | 1 | 2008 | 141 | 0.290 |
Why?
|
| Lipid Metabolism Disorders | 2 | 2020 | 20 | 0.290 |
Why?
|
| Fibric Acids | 3 | 2017 | 27 | 0.290 |
Why?
|
| Patient Discharge | 1 | 2020 | 3442 | 0.290 |
Why?
|
| Pancreatitis | 1 | 2014 | 1097 | 0.280 |
Why?
|
| Hypoglycemic Agents | 6 | 2020 | 3085 | 0.280 |
Why?
|
| Parents | 2 | 2018 | 3563 | 0.280 |
Why?
|
| Arteriosclerosis | 4 | 2005 | 1056 | 0.280 |
Why?
|
| Regional Blood Flow | 8 | 2010 | 1496 | 0.280 |
Why?
|
| Lipolysis | 1 | 2008 | 211 | 0.280 |
Why?
|
| Prognosis | 17 | 2021 | 29600 | 0.280 |
Why?
|
| Kidney Failure, Chronic | 3 | 2011 | 2477 | 0.270 |
Why?
|
| Stroke | 5 | 2021 | 9712 | 0.270 |
Why?
|
| Sodium Fluoride | 3 | 2021 | 65 | 0.260 |
Why?
|
| Antigens, CD1d | 4 | 2017 | 228 | 0.260 |
Why?
|
| Mutation, Missense | 2 | 2014 | 2570 | 0.260 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2007 | 214 | 0.260 |
Why?
|
| Age Factors | 10 | 2020 | 18381 | 0.260 |
Why?
|
| Regression Analysis | 13 | 2016 | 6338 | 0.260 |
Why?
|
| Intestines | 3 | 2013 | 1909 | 0.260 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 4 | 2018 | 224 | 0.260 |
Why?
|
| Leucine | 8 | 2014 | 548 | 0.260 |
Why?
|
| Taiwan | 2 | 2019 | 521 | 0.260 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3088 | 0.260 |
Why?
|
| Gastrectomy | 1 | 2010 | 671 | 0.260 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3209 | 0.250 |
Why?
|
| Drug Delivery Systems | 3 | 2020 | 2222 | 0.250 |
Why?
|
| Preventive Medicine | 1 | 2007 | 245 | 0.250 |
Why?
|
| Insulin | 13 | 2015 | 6593 | 0.250 |
Why?
|
| Ultrasonography | 9 | 2018 | 5964 | 0.250 |
Why?
|
| Biological Transport | 6 | 2015 | 2089 | 0.250 |
Why?
|
| Nephrotic Syndrome | 3 | 2007 | 390 | 0.250 |
Why?
|
| PPAR alpha | 2 | 2019 | 175 | 0.250 |
Why?
|
| Bile Acids and Salts | 2 | 2020 | 393 | 0.240 |
Why?
|
| Oligonucleotides, Antisense | 2 | 2021 | 458 | 0.240 |
Why?
|
| Phospholipids | 4 | 2014 | 786 | 0.240 |
Why?
|
| Brazil | 2 | 2019 | 1228 | 0.240 |
Why?
|
| Nitric Oxide Synthase | 2 | 2007 | 908 | 0.240 |
Why?
|
| Dietary Fats | 4 | 2018 | 1995 | 0.240 |
Why?
|
| Platelet Activation | 3 | 2018 | 646 | 0.240 |
Why?
|
| Health Behavior | 1 | 2016 | 2643 | 0.240 |
Why?
|
| Apolipoproteins C | 6 | 2011 | 59 | 0.240 |
Why?
|
| Clinical Laboratory Techniques | 3 | 2020 | 745 | 0.230 |
Why?
|
| Vitamins | 2 | 2021 | 1635 | 0.230 |
Why?
|
| China | 4 | 2019 | 2374 | 0.230 |
Why?
|
| Inflammation | 11 | 2020 | 10760 | 0.230 |
Why?
|
| C-Reactive Protein | 10 | 2019 | 3822 | 0.230 |
Why?
|
| Databases, Factual | 2 | 2016 | 7960 | 0.230 |
Why?
|
| Residence Characteristics | 1 | 2014 | 2090 | 0.230 |
Why?
|
| Antioxidants | 5 | 2020 | 1668 | 0.230 |
Why?
|
| Interleukin-6 | 9 | 2020 | 3206 | 0.230 |
Why?
|
| Dose-Response Relationship, Drug | 12 | 2020 | 10754 | 0.230 |
Why?
|
| MicroRNAs | 2 | 2018 | 3805 | 0.220 |
Why?
|
| Nitroglycerin | 5 | 2015 | 329 | 0.220 |
Why?
|
| Population Surveillance | 1 | 2014 | 2595 | 0.220 |
Why?
|
| Body Mass Index | 17 | 2020 | 12943 | 0.220 |
Why?
|
| Placebos | 10 | 2018 | 1667 | 0.220 |
Why?
|
| Guidelines as Topic | 3 | 2016 | 1386 | 0.220 |
Why?
|
| Enzyme Inhibitors | 4 | 2009 | 3705 | 0.220 |
Why?
|
| Congresses as Topic | 1 | 2008 | 802 | 0.210 |
Why?
|
| Sex Factors | 8 | 2020 | 10548 | 0.210 |
Why?
|
| Quality Improvement | 1 | 2018 | 3797 | 0.210 |
Why?
|
| Erectile Dysfunction | 1 | 2006 | 444 | 0.210 |
Why?
|
| Synovial Fluid | 4 | 2020 | 393 | 0.210 |
Why?
|
| Biomedical Research | 2 | 2017 | 3426 | 0.210 |
Why?
|
| Fatty Acids, Omega-6 | 2 | 2015 | 225 | 0.210 |
Why?
|
| Ventricular Dysfunction | 1 | 2003 | 144 | 0.210 |
Why?
|
| Cooperative Behavior | 4 | 2018 | 1504 | 0.210 |
Why?
|
| Health Care Costs | 4 | 2020 | 3238 | 0.210 |
Why?
|
| Genetic Variation | 3 | 2021 | 6561 | 0.200 |
Why?
|
| Up-Regulation | 7 | 2020 | 4117 | 0.200 |
Why?
|
| Exercise | 4 | 2018 | 5886 | 0.200 |
Why?
|
| Electronic Health Records | 2 | 2016 | 4803 | 0.200 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2020 | 15908 | 0.200 |
Why?
|
| Pediatrics | 1 | 2017 | 3588 | 0.200 |
Why?
|
| Hong Kong | 2 | 2019 | 163 | 0.200 |
Why?
|
| Metabolic Diseases | 1 | 2008 | 680 | 0.200 |
Why?
|
| Follow-Up Studies | 11 | 2019 | 39063 | 0.200 |
Why?
|
| Kidney Diseases | 2 | 2011 | 2090 | 0.200 |
Why?
|
| Body Composition | 4 | 2010 | 2426 | 0.190 |
Why?
|
| Lymphocyte Activation | 5 | 2019 | 5463 | 0.190 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 2017 | 799 | 0.190 |
Why?
|
| Galactosylceramides | 3 | 2017 | 92 | 0.190 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2017 | 1169 | 0.190 |
Why?
|
| Antigens, CD1 | 5 | 2012 | 439 | 0.190 |
Why?
|
| RNA, Messenger | 4 | 2017 | 12758 | 0.190 |
Why?
|
| Drug Tolerance | 2 | 2021 | 367 | 0.190 |
Why?
|
| Interleukin-12 | 3 | 2019 | 577 | 0.190 |
Why?
|
| Subtilisins | 1 | 2021 | 81 | 0.190 |
Why?
|
| Quality of Health Care | 1 | 2016 | 4321 | 0.180 |
Why?
|
| Vitamin K 1 | 1 | 2021 | 47 | 0.180 |
Why?
|
| Down-Regulation | 6 | 2019 | 2915 | 0.180 |
Why?
|
| Time Factors | 18 | 2020 | 39913 | 0.180 |
Why?
|
| Xanthomatosis | 2 | 2018 | 32 | 0.180 |
Why?
|
| Heredity | 3 | 2018 | 148 | 0.180 |
Why?
|
| Nitric Oxide | 2 | 2011 | 2135 | 0.180 |
Why?
|
| Cardiovascular Agents | 1 | 2007 | 839 | 0.180 |
Why?
|
| Smoking | 6 | 2018 | 9050 | 0.180 |
Why?
|
| Cholesterol Ester Transfer Proteins | 3 | 2007 | 113 | 0.180 |
Why?
|
| Fluorine Radioisotopes | 2 | 2020 | 418 | 0.180 |
Why?
|
| Interleukin-18 | 2 | 2019 | 250 | 0.180 |
Why?
|
| Case-Control Studies | 14 | 2020 | 22148 | 0.180 |
Why?
|
| Pharmaceutical Preparations | 1 | 2008 | 1086 | 0.180 |
Why?
|
| Queensland | 1 | 2020 | 52 | 0.180 |
Why?
|
| Waist Circumference | 5 | 2020 | 933 | 0.180 |
Why?
|
| Patient Selection | 3 | 2019 | 4237 | 0.170 |
Why?
|
| Matrix Metalloproteinase 3 | 3 | 2020 | 138 | 0.170 |
Why?
|
| New Zealand | 4 | 2015 | 358 | 0.170 |
Why?
|
| Prospective Studies | 18 | 2021 | 54360 | 0.170 |
Why?
|
| Hyperlipoproteinemia Type I | 1 | 2019 | 11 | 0.170 |
Why?
|
| Radiopharmaceuticals | 2 | 2020 | 2650 | 0.170 |
Why?
|
| Obesity, Morbid | 1 | 2010 | 1276 | 0.170 |
Why?
|
| Colchicine | 1 | 2021 | 259 | 0.170 |
Why?
|
| Inflammation Mediators | 3 | 2018 | 1884 | 0.170 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2004 | 858 | 0.160 |
Why?
|
| Blood Flow Velocity | 5 | 2009 | 1370 | 0.160 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2021 | 155 | 0.160 |
Why?
|
| Arterioles | 2 | 2010 | 250 | 0.160 |
Why?
|
| Alzheimer Disease | 1 | 2021 | 8601 | 0.160 |
Why?
|
| Nutrition Surveys | 2 | 2018 | 1723 | 0.160 |
Why?
|
| Chemistry, Clinical | 2 | 2016 | 64 | 0.160 |
Why?
|
| Elasticity | 3 | 2007 | 655 | 0.160 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2020 | 4341 | 0.160 |
Why?
|
| Signal Transduction | 13 | 2020 | 23416 | 0.160 |
Why?
|
| Endothelial Cells | 5 | 2020 | 3548 | 0.160 |
Why?
|
| Primary Prevention | 3 | 2019 | 1185 | 0.160 |
Why?
|
| Markov Chains | 2 | 2020 | 965 | 0.160 |
Why?
|
| Plethysmography | 4 | 2006 | 175 | 0.160 |
Why?
|
| Social Support | 2 | 2020 | 2174 | 0.160 |
Why?
|
| Interdisciplinary Communication | 2 | 2014 | 928 | 0.160 |
Why?
|
| Butyrates | 1 | 2019 | 169 | 0.150 |
Why?
|
| Logistic Models | 5 | 2019 | 13245 | 0.150 |
Why?
|
| Benzoxazoles | 1 | 2019 | 90 | 0.150 |
Why?
|
| Albuminuria | 2 | 2014 | 655 | 0.150 |
Why?
|
| Antihypertensive Agents | 3 | 2017 | 2016 | 0.150 |
Why?
|
| Compliance | 2 | 2010 | 100 | 0.150 |
Why?
|
| Research Design | 5 | 2017 | 6174 | 0.150 |
Why?
|
| Disease Progression | 5 | 2020 | 13495 | 0.150 |
Why?
|
| Antigen Presentation | 3 | 2010 | 1250 | 0.150 |
Why?
|
| Retrospective Studies | 16 | 2021 | 80566 | 0.150 |
Why?
|
| Diabetes Mellitus | 5 | 2020 | 5835 | 0.150 |
Why?
|
| Antibodies, Viral | 2 | 2021 | 3150 | 0.150 |
Why?
|
| Fatty Acids, Monounsaturated | 2 | 2015 | 190 | 0.150 |
Why?
|
| Reference Values | 6 | 2021 | 4919 | 0.140 |
Why?
|
| Receptors, OSM-LIF | 1 | 2017 | 15 | 0.140 |
Why?
|
| Interleukin-1alpha | 1 | 2017 | 86 | 0.140 |
Why?
|
| Antigens, Bacterial | 3 | 2013 | 1141 | 0.140 |
Why?
|
| Anthropometry | 3 | 2012 | 1338 | 0.140 |
Why?
|
| Community Mental Health Services | 1 | 2020 | 389 | 0.140 |
Why?
|
| Glycoproteins | 3 | 2010 | 2200 | 0.140 |
Why?
|
| Efficiency | 1 | 2020 | 476 | 0.140 |
Why?
|
| Risk | 5 | 2017 | 9604 | 0.140 |
Why?
|
| Severity of Illness Index | 9 | 2018 | 15828 | 0.140 |
Why?
|
| Blood Vessels | 1 | 2003 | 1113 | 0.140 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2019 | 368 | 0.140 |
Why?
|
| Leukemia Inhibitory Factor | 1 | 2017 | 77 | 0.140 |
Why?
|
| Apolipoprotein C-II | 1 | 2016 | 15 | 0.140 |
Why?
|
| Leukotriene B4 | 1 | 2018 | 280 | 0.140 |
Why?
|
| Liposomes | 2 | 2019 | 784 | 0.140 |
Why?
|
| Nutrition Policy | 1 | 2020 | 466 | 0.140 |
Why?
|
| Quality-Adjusted Life Years | 2 | 2020 | 1722 | 0.140 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 2014 | 1492 | 0.140 |
Why?
|
| RNA, Small Interfering | 4 | 2020 | 3419 | 0.140 |
Why?
|
| Delayed-Action Preparations | 3 | 2015 | 962 | 0.140 |
Why?
|
| Molecular Targeted Therapy | 3 | 2019 | 2812 | 0.130 |
Why?
|
| Awareness | 1 | 2021 | 649 | 0.130 |
Why?
|
| Cytokines | 6 | 2019 | 7373 | 0.130 |
Why?
|
| Coronary Angiography | 5 | 2020 | 4470 | 0.130 |
Why?
|
| Asia | 1 | 2018 | 615 | 0.130 |
Why?
|
| Deuterium | 2 | 2015 | 106 | 0.130 |
Why?
|
| Evidence-Based Medicine | 4 | 2018 | 3680 | 0.130 |
Why?
|
| Allopurinol | 1 | 2018 | 198 | 0.130 |
Why?
|
| Postmenopause | 2 | 2015 | 2511 | 0.130 |
Why?
|
| Immunoglobulin M | 1 | 2021 | 1526 | 0.130 |
Why?
|
| Tunica Intima | 2 | 2009 | 459 | 0.130 |
Why?
|
| Autocrine Communication | 1 | 2017 | 169 | 0.130 |
Why?
|
| Loneliness | 1 | 2018 | 203 | 0.130 |
Why?
|
| Gene Expression Regulation | 6 | 2019 | 11874 | 0.130 |
Why?
|
| Linear Models | 5 | 2020 | 5866 | 0.130 |
Why?
|
| Multifactorial Inheritance | 2 | 2014 | 1380 | 0.130 |
Why?
|
| Alcohols | 2 | 2008 | 94 | 0.130 |
Why?
|
| Administration, Oral | 7 | 2020 | 4010 | 0.130 |
Why?
|
| Overweight | 3 | 2016 | 2417 | 0.130 |
Why?
|
| Serum Amyloid P-Component | 1 | 2016 | 46 | 0.130 |
Why?
|
| Norpregnenes | 1 | 2015 | 6 | 0.130 |
Why?
|
| Particle Size | 5 | 2015 | 1648 | 0.130 |
Why?
|
| Pulse | 2 | 2006 | 217 | 0.130 |
Why?
|
| Heart Rate | 5 | 2013 | 4180 | 0.130 |
Why?
|
| Medical History Taking | 3 | 2020 | 773 | 0.130 |
Why?
|
| Social Perception | 1 | 2019 | 431 | 0.130 |
Why?
|
| Social Isolation | 1 | 2018 | 364 | 0.130 |
Why?
|
| Expert Systems | 1 | 2015 | 79 | 0.120 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2019 | 385 | 0.120 |
Why?
|
| Plasma | 1 | 2018 | 586 | 0.120 |
Why?
|
| Osteoarthritis | 3 | 2019 | 1063 | 0.120 |
Why?
|
| Thiazoles | 2 | 2014 | 1517 | 0.120 |
Why?
|
| Protease Inhibitors | 1 | 2018 | 753 | 0.120 |
Why?
|
| Fish Oils | 4 | 2018 | 483 | 0.120 |
Why?
|
| Nitric Oxide Synthase Type III | 2 | 2011 | 705 | 0.120 |
Why?
|
| Aged, 80 and over | 12 | 2021 | 58894 | 0.120 |
Why?
|
| Glomerular Filtration Rate | 3 | 2015 | 2178 | 0.120 |
Why?
|
| Drug Compounding | 4 | 2020 | 245 | 0.120 |
Why?
|
| Sphingomyelins | 1 | 2015 | 105 | 0.120 |
Why?
|
| Genetics, Population | 1 | 2019 | 935 | 0.120 |
Why?
|
| Glucosylceramides | 1 | 2014 | 28 | 0.120 |
Why?
|
| Peroxidase | 1 | 2018 | 610 | 0.120 |
Why?
|
| Rare Diseases | 1 | 2020 | 622 | 0.120 |
Why?
|
| Self-Help Groups | 1 | 2016 | 192 | 0.120 |
Why?
|
| Patient Care Team | 2 | 2020 | 2515 | 0.120 |
Why?
|
| Exercise Therapy | 2 | 2016 | 929 | 0.120 |
Why?
|
| Glutathione | 1 | 2017 | 582 | 0.120 |
Why?
|
| Comorbidity | 6 | 2020 | 10505 | 0.120 |
Why?
|
| Affective Disorders, Psychotic | 1 | 2015 | 186 | 0.120 |
Why?
|
| Models, Psychological | 1 | 2018 | 829 | 0.120 |
Why?
|
| Neutrophils | 2 | 2018 | 3763 | 0.120 |
Why?
|
| Data Mining | 2 | 2016 | 551 | 0.120 |
Why?
|
| Chylomicron Remnants | 2 | 2012 | 3 | 0.110 |
Why?
|
| Chalcones | 1 | 2014 | 30 | 0.110 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2015 | 277 | 0.110 |
Why?
|
| Interleukin-17 | 1 | 2020 | 911 | 0.110 |
Why?
|
| Ceramides | 1 | 2015 | 200 | 0.110 |
Why?
|
| Myocardial Revascularization | 1 | 2017 | 790 | 0.110 |
Why?
|
| Cost Sharing | 1 | 2017 | 409 | 0.110 |
Why?
|
| Interinstitutional Relations | 1 | 2014 | 236 | 0.110 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2019 | 2118 | 0.110 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2006 | 1875 | 0.110 |
Why?
|
| Cells, Cultured | 10 | 2020 | 18937 | 0.110 |
Why?
|
| Internet | 2 | 2016 | 3090 | 0.110 |
Why?
|
| Reproducibility of Results | 8 | 2019 | 20074 | 0.110 |
Why?
|
| Propionates | 1 | 2014 | 183 | 0.110 |
Why?
|
| Drug Interactions | 1 | 2017 | 1415 | 0.110 |
Why?
|
| Serine | 1 | 2017 | 830 | 0.110 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2015 | 426 | 0.110 |
Why?
|
| Transcription Factors | 3 | 2020 | 12116 | 0.110 |
Why?
|
| Clinical Chemistry Tests | 1 | 2013 | 59 | 0.110 |
Why?
|
| South Africa | 1 | 2018 | 1836 | 0.110 |
Why?
|
| Antigen-Presenting Cells | 3 | 2013 | 963 | 0.110 |
Why?
|
| Sphingolipids | 1 | 2014 | 173 | 0.100 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2019 | 1835 | 0.100 |
Why?
|
| NAD | 1 | 2017 | 614 | 0.100 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 1 | 2012 | 57 | 0.100 |
Why?
|
| Quality of Life | 4 | 2020 | 13347 | 0.100 |
Why?
|
| T-Lymphocyte Subsets | 3 | 2019 | 1798 | 0.100 |
Why?
|
| Single-Blind Method | 3 | 2013 | 1575 | 0.100 |
Why?
|
| Cholic Acids | 1 | 2012 | 39 | 0.100 |
Why?
|
| Sensitivity and Specificity | 5 | 2021 | 14648 | 0.100 |
Why?
|
| Cholesterol Esters | 2 | 2002 | 73 | 0.100 |
Why?
|
| Consanguinity | 1 | 2014 | 456 | 0.100 |
Why?
|
| Multivariate Analysis | 6 | 2020 | 12043 | 0.100 |
Why?
|
| Aortic Valve | 2 | 2021 | 1955 | 0.100 |
Why?
|
| Insulin-Secreting Cells | 1 | 2020 | 898 | 0.100 |
Why?
|
| Republic of Korea | 1 | 2014 | 583 | 0.100 |
Why?
|
| Acetates | 1 | 2014 | 321 | 0.100 |
Why?
|
| ADP-Ribosylation Factors | 1 | 2012 | 133 | 0.100 |
Why?
|
| Health Education | 1 | 2019 | 1049 | 0.100 |
Why?
|
| Health Services | 1 | 2017 | 751 | 0.100 |
Why?
|
| Self Efficacy | 1 | 2016 | 636 | 0.100 |
Why?
|
| Death | 1 | 2016 | 674 | 0.100 |
Why?
|
| Spain | 3 | 2019 | 487 | 0.100 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2019 | 3634 | 0.100 |
Why?
|
| von Willebrand Factor | 1 | 2015 | 676 | 0.100 |
Why?
|
| Protein Structure, Secondary | 1 | 2015 | 1229 | 0.100 |
Why?
|
| Data Interpretation, Statistical | 2 | 2016 | 2689 | 0.100 |
Why?
|
| PPAR delta | 1 | 2011 | 40 | 0.100 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2011 | 145 | 0.100 |
Why?
|
| Ideal Body Weight | 1 | 2011 | 27 | 0.090 |
Why?
|
| ROC Curve | 1 | 2019 | 3575 | 0.090 |
Why?
|
| Models, Organizational | 1 | 2014 | 544 | 0.090 |
Why?
|
| Premenopause | 1 | 2015 | 1038 | 0.090 |
Why?
|
| Endothelin-1 | 1 | 2013 | 302 | 0.090 |
Why?
|
| Radial Artery | 1 | 2013 | 187 | 0.090 |
Why?
|
| Attitude | 1 | 2016 | 772 | 0.090 |
Why?
|
| Endocytosis | 2 | 2012 | 955 | 0.090 |
Why?
|
| F2-Isoprostanes | 4 | 2016 | 35 | 0.090 |
Why?
|
| Repressor Proteins | 2 | 2020 | 2985 | 0.090 |
Why?
|
| Lymphocytes | 1 | 2019 | 2604 | 0.090 |
Why?
|
| Angiography | 1 | 2016 | 1596 | 0.090 |
Why?
|
| Anticoagulants | 2 | 2018 | 4785 | 0.090 |
Why?
|
| Diagnosis, Differential | 3 | 2014 | 12966 | 0.090 |
Why?
|
| American Heart Association | 1 | 2015 | 1039 | 0.090 |
Why?
|
| beta-Glucans | 1 | 2011 | 123 | 0.090 |
Why?
|
| Atrial Fibrillation | 2 | 2021 | 5031 | 0.090 |
Why?
|
| Calcium | 2 | 2021 | 5717 | 0.090 |
Why?
|
| Program Development | 1 | 2017 | 1293 | 0.090 |
Why?
|
| Community Networks | 1 | 2012 | 201 | 0.090 |
Why?
|
| Hyperemia | 1 | 2012 | 221 | 0.090 |
Why?
|
| Telephone | 1 | 2014 | 626 | 0.090 |
Why?
|
| Drug Combinations | 2 | 2016 | 2048 | 0.090 |
Why?
|
| Cardiovascular System | 2 | 2016 | 834 | 0.090 |
Why?
|
| Apolipoproteins E | 2 | 2015 | 1443 | 0.090 |
Why?
|
| Homeodomain Proteins | 1 | 2020 | 2413 | 0.090 |
Why?
|
| Coronary Vessels | 2 | 2020 | 3095 | 0.090 |
Why?
|
| Caloric Restriction | 1 | 2013 | 299 | 0.090 |
Why?
|
| HIV Infections | 2 | 2019 | 17337 | 0.090 |
Why?
|
| Aspergillus fumigatus | 1 | 2011 | 157 | 0.090 |
Why?
|
| Pathology, Clinical | 1 | 2014 | 376 | 0.090 |
Why?
|
| Prediabetic State | 1 | 2016 | 545 | 0.090 |
Why?
|
| Japan | 1 | 2014 | 1372 | 0.090 |
Why?
|
| Sulfoglycosphingolipids | 1 | 2009 | 29 | 0.090 |
Why?
|
| Antigens | 2 | 2015 | 1441 | 0.090 |
Why?
|
| Genetic Counseling | 1 | 2014 | 627 | 0.090 |
Why?
|
| Calcinosis | 1 | 2018 | 1469 | 0.090 |
Why?
|
| Sex Characteristics | 1 | 2020 | 2637 | 0.090 |
Why?
|
| Diabetic Cardiomyopathies | 1 | 2011 | 90 | 0.090 |
Why?
|
| Immunoassay | 3 | 2010 | 744 | 0.090 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2019 | 1228 | 0.090 |
Why?
|
| Drug Design | 1 | 2015 | 1045 | 0.080 |
Why?
|
| Immunologic Factors | 1 | 2019 | 1589 | 0.080 |
Why?
|
| Age Distribution | 4 | 2016 | 2871 | 0.080 |
Why?
|
| Aspergillosis | 1 | 2011 | 242 | 0.080 |
Why?
|
| Cytomegalovirus Infections | 1 | 2016 | 828 | 0.080 |
Why?
|
| Biological Products | 1 | 2019 | 912 | 0.080 |
Why?
|
| Glycosphingolipids | 1 | 2010 | 73 | 0.080 |
Why?
|
| Decision Trees | 1 | 2011 | 504 | 0.080 |
Why?
|
| Homocysteine | 3 | 2008 | 638 | 0.080 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2020 | 2895 | 0.080 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 2020 | 0.080 |
Why?
|
| Immunoglobulin G | 1 | 2021 | 4533 | 0.080 |
Why?
|
| Income | 1 | 2018 | 1870 | 0.080 |
Why?
|
| Lipoproteins, IDL | 3 | 2003 | 18 | 0.080 |
Why?
|
| Blood Coagulation | 1 | 2015 | 1154 | 0.080 |
Why?
|
| Fruit | 1 | 2014 | 1157 | 0.080 |
Why?
|
| Mice | 20 | 2020 | 81368 | 0.080 |
Why?
|
| Vegetables | 1 | 2014 | 1191 | 0.080 |
Why?
|
| Community Health Services | 1 | 2014 | 654 | 0.080 |
Why?
|
| Blood Platelets | 2 | 2010 | 2478 | 0.080 |
Why?
|
| Anaphylaxis | 1 | 2016 | 757 | 0.080 |
Why?
|
| Models, Economic | 1 | 2013 | 714 | 0.080 |
Why?
|
| Evidence-Based Practice | 1 | 2013 | 494 | 0.080 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2015 | 1117 | 0.080 |
Why?
|
| Cell Wall | 1 | 2011 | 420 | 0.080 |
Why?
|
| Alberta | 1 | 2008 | 68 | 0.080 |
Why?
|
| omega-N-Methylarginine | 2 | 2005 | 108 | 0.080 |
Why?
|
| Mast Cells | 2 | 2008 | 1392 | 0.080 |
Why?
|
| Trichinellosis | 1 | 2008 | 27 | 0.080 |
Why?
|
| Trichinella spiralis | 1 | 2008 | 22 | 0.080 |
Why?
|
| Triazoles | 1 | 2014 | 903 | 0.080 |
Why?
|
| Drug Prescriptions | 1 | 2018 | 1669 | 0.080 |
Why?
|
| Quinolines | 1 | 2014 | 764 | 0.080 |
Why?
|
| Cohort Studies | 11 | 2021 | 41457 | 0.080 |
Why?
|
| Cell-Derived Microparticles | 1 | 2010 | 161 | 0.080 |
Why?
|
| Patient Care Management | 1 | 2011 | 302 | 0.080 |
Why?
|
| Referral and Consultation | 3 | 2016 | 3599 | 0.080 |
Why?
|
| Nanoparticles | 1 | 2020 | 1957 | 0.080 |
Why?
|
| Ultracentrifugation | 1 | 2008 | 183 | 0.070 |
Why?
|
| Nitroprusside | 2 | 2005 | 272 | 0.070 |
Why?
|
| Diastole | 2 | 2008 | 781 | 0.070 |
Why?
|
| Thiazolidinediones | 1 | 2011 | 460 | 0.070 |
Why?
|
| Carbon Isotopes | 3 | 2003 | 458 | 0.070 |
Why?
|
| Thymus Gland | 1 | 2012 | 1243 | 0.070 |
Why?
|
| Esters | 2 | 2013 | 211 | 0.070 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2005 | 1650 | 0.070 |
Why?
|
| Aging | 2 | 2020 | 8699 | 0.070 |
Why?
|
| Metabolomics | 1 | 2017 | 1656 | 0.070 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2007 | 32 | 0.070 |
Why?
|
| Tunica Media | 1 | 2007 | 112 | 0.070 |
Why?
|
| Proteins | 2 | 2017 | 6030 | 0.070 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2007 | 56 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2016 | 3800 | 0.070 |
Why?
|
| Adaptation, Biological | 1 | 2008 | 147 | 0.070 |
Why?
|
| Interviews as Topic | 1 | 2014 | 2697 | 0.070 |
Why?
|
| Thrombosis | 2 | 2018 | 2943 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 4739 | 0.070 |
Why?
|
| Retinol-Binding Proteins, Plasma | 1 | 2007 | 94 | 0.070 |
Why?
|
| Tryptases | 1 | 2008 | 176 | 0.070 |
Why?
|
| Attitude of Health Personnel | 2 | 2018 | 3879 | 0.070 |
Why?
|
| Interleukins | 1 | 2011 | 783 | 0.070 |
Why?
|
| Analysis of Variance | 3 | 2012 | 6224 | 0.070 |
Why?
|
| Diet, Mediterranean | 1 | 2013 | 738 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 6074 | 0.070 |
Why?
|
| Smoking Cessation | 1 | 2018 | 2056 | 0.070 |
Why?
|
| GATA6 Transcription Factor | 1 | 2006 | 50 | 0.070 |
Why?
|
| World Health Organization | 2 | 2016 | 1321 | 0.070 |
Why?
|
| Publication Bias | 2 | 2018 | 160 | 0.070 |
Why?
|
| Cell Proliferation | 2 | 2019 | 10432 | 0.070 |
Why?
|
| Critical Pathways | 1 | 2010 | 474 | 0.070 |
Why?
|
| Aortic Valve Stenosis | 1 | 2018 | 2003 | 0.070 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 2371 | 0.070 |
Why?
|
| Pandemics | 3 | 2020 | 8645 | 0.070 |
Why?
|
| Acetylcholine | 2 | 2005 | 629 | 0.060 |
Why?
|
| Racemases and Epimerases | 1 | 2006 | 114 | 0.060 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 9417 | 0.060 |
Why?
|
| Coenzymes | 2 | 2003 | 102 | 0.060 |
Why?
|
| Confidence Intervals | 1 | 2011 | 2925 | 0.060 |
Why?
|
| Hyperandrogenism | 1 | 2005 | 39 | 0.060 |
Why?
|
| Catecholamines | 1 | 2006 | 387 | 0.060 |
Why?
|
| Meta-Analysis as Topic | 1 | 2010 | 1380 | 0.060 |
Why?
|
| Heart | 1 | 2018 | 4403 | 0.060 |
Why?
|
| DNA | 2 | 2019 | 7196 | 0.060 |
Why?
|
| Stroke Volume | 2 | 2013 | 5486 | 0.060 |
Why?
|
| Hypertension, Pulmonary | 1 | 2016 | 1580 | 0.060 |
Why?
|
| Drug Synergism | 1 | 2009 | 1755 | 0.060 |
Why?
|
| Hypotension | 1 | 2011 | 878 | 0.060 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2015 | 2270 | 0.060 |
Why?
|
| Immunity, Innate | 3 | 2019 | 3045 | 0.060 |
Why?
|
| Societies, Medical | 4 | 2020 | 3900 | 0.060 |
Why?
|
| Isotopes | 1 | 2004 | 125 | 0.060 |
Why?
|
| STAT4 Transcription Factor | 2 | 2017 | 93 | 0.060 |
Why?
|
| Venous Thromboembolism | 1 | 2018 | 1866 | 0.060 |
Why?
|
| Radioactive Tracers | 2 | 2015 | 66 | 0.060 |
Why?
|
| Sialic Acids | 1 | 2004 | 123 | 0.060 |
Why?
|
| Europe | 3 | 2016 | 3413 | 0.060 |
Why?
|
| Breath Tests | 2 | 2003 | 299 | 0.060 |
Why?
|
| Eating | 1 | 2011 | 1535 | 0.060 |
Why?
|
| Receptor, Insulin | 1 | 2008 | 836 | 0.060 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2007 | 563 | 0.060 |
Why?
|
| Protons | 1 | 2009 | 1112 | 0.060 |
Why?
|
| Hospital Mortality | 1 | 2018 | 5293 | 0.060 |
Why?
|
| Survival Rate | 1 | 2018 | 12719 | 0.060 |
Why?
|
| Decision Making | 1 | 2017 | 3918 | 0.060 |
Why?
|
| Developing Countries | 1 | 2016 | 2867 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2005 | 453 | 0.050 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 2 | 2017 | 265 | 0.050 |
Why?
|
| Quality Indicators, Health Care | 1 | 2013 | 1790 | 0.050 |
Why?
|
| Milk | 2 | 2017 | 442 | 0.050 |
Why?
|
| Sterols | 1 | 2003 | 64 | 0.050 |
Why?
|
| Fat Emulsions, Intravenous | 1 | 2006 | 314 | 0.050 |
Why?
|
| Protein Transport | 4 | 2013 | 1966 | 0.050 |
Why?
|
| Placebo Effect | 2 | 2018 | 518 | 0.050 |
Why?
|
| Photoplethysmography | 1 | 2003 | 63 | 0.050 |
Why?
|
| Quality Assurance, Health Care | 1 | 2013 | 2164 | 0.050 |
Why?
|
| Myeloid Differentiation Factor 88 | 2 | 2020 | 584 | 0.050 |
Why?
|
| Clinical Competence | 1 | 2018 | 4789 | 0.050 |
Why?
|
| Hypertension, Renal | 1 | 2003 | 135 | 0.050 |
Why?
|
| Ischemia | 2 | 2020 | 1884 | 0.050 |
Why?
|
| Intracellular Fluid | 1 | 2002 | 201 | 0.050 |
Why?
|
| Child, Preschool | 5 | 2019 | 42188 | 0.050 |
Why?
|
| Monomeric Clathrin Assembly Proteins | 1 | 2002 | 24 | 0.050 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2007 | 709 | 0.050 |
Why?
|
| Finland | 2 | 2015 | 607 | 0.050 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 2002 | 60 | 0.050 |
Why?
|
| Asparagine | 1 | 2002 | 119 | 0.050 |
Why?
|
| Feeding Behavior | 1 | 2014 | 3182 | 0.050 |
Why?
|
| Oxazolone | 1 | 2002 | 61 | 0.050 |
Why?
|
| Genomics | 1 | 2018 | 5822 | 0.050 |
Why?
|
| Blood Circulation | 1 | 2003 | 248 | 0.050 |
Why?
|
| Antipsychotic Agents | 1 | 2015 | 3066 | 0.050 |
Why?
|
| Electron Transport | 1 | 2003 | 210 | 0.050 |
Why?
|
| Drug Administration Schedule | 3 | 2018 | 4845 | 0.050 |
Why?
|
| Central Nervous System Depressants | 1 | 2003 | 164 | 0.050 |
Why?
|
| Lipopolysaccharides | 1 | 2009 | 2202 | 0.050 |
Why?
|
| Patient Education as Topic | 1 | 2012 | 2315 | 0.050 |
Why?
|
| Retroperitoneal Space | 1 | 2002 | 170 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2018 | 6483 | 0.050 |
Why?
|
| Protein Binding | 5 | 2019 | 9345 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 7 | 2020 | 22115 | 0.050 |
Why?
|
| Electric Impedance | 2 | 2004 | 751 | 0.050 |
Why?
|
| Health Promotion | 2 | 2013 | 2206 | 0.050 |
Why?
|
| Fibrinolysis | 1 | 2003 | 331 | 0.050 |
Why?
|
| Collagen | 1 | 2010 | 2634 | 0.050 |
Why?
|
| Peritoneum | 1 | 2002 | 225 | 0.050 |
Why?
|
| Plasmapheresis | 1 | 2002 | 206 | 0.050 |
Why?
|
| Protein Isoforms | 3 | 2019 | 1697 | 0.050 |
Why?
|
| Autonomic Nervous System | 1 | 2006 | 704 | 0.050 |
Why?
|
| Sulfhydryl Compounds | 1 | 2002 | 301 | 0.050 |
Why?
|
| Health Care Surveys | 2 | 2018 | 2423 | 0.050 |
Why?
|
| Age of Onset | 2 | 2018 | 3302 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2014 | 8618 | 0.050 |
Why?
|
| Kidney Transplantation | 1 | 2016 | 4236 | 0.050 |
Why?
|
| Immunoglobulin E | 2 | 2008 | 1502 | 0.050 |
Why?
|
| Cell Adhesion | 3 | 2019 | 3088 | 0.050 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2020 | 81 | 0.050 |
Why?
|
| Interleukin-13 | 1 | 2003 | 392 | 0.050 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 12447 | 0.040 |
Why?
|
| Aspirin | 2 | 2018 | 3127 | 0.040 |
Why?
|
| Menopause | 2 | 2020 | 1645 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2021 | 273 | 0.040 |
Why?
|
| Tea | 1 | 2002 | 287 | 0.040 |
Why?
|
| Chemokine CXCL2 | 1 | 2020 | 106 | 0.040 |
Why?
|
| Chronic Disease | 3 | 2011 | 9311 | 0.040 |
Why?
|
| Monocytes | 2 | 2020 | 2565 | 0.040 |
Why?
|
| Amides | 1 | 2002 | 449 | 0.040 |
Why?
|
| Sex Distribution | 2 | 2016 | 2278 | 0.040 |
Why?
|
| Serbia | 1 | 2019 | 13 | 0.040 |
Why?
|
| Cell Line | 6 | 2013 | 15576 | 0.040 |
Why?
|
| Membrane Proteins | 3 | 2008 | 7847 | 0.040 |
Why?
|
| Receptors, Chemokine | 1 | 2003 | 652 | 0.040 |
Why?
|
| Chemokine CXCL1 | 1 | 2020 | 101 | 0.040 |
Why?
|
| Abdomen | 2 | 2004 | 1128 | 0.040 |
Why?
|
| Echocardiography | 2 | 2009 | 4987 | 0.040 |
Why?
|
| Echocardiography, Doppler | 1 | 2003 | 893 | 0.040 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2003 | 540 | 0.040 |
Why?
|
| Transfection | 3 | 2015 | 5766 | 0.040 |
Why?
|
| Platelet Aggregation | 1 | 2003 | 771 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2002 | 672 | 0.040 |
Why?
|
| Phosphorylation | 3 | 2019 | 8311 | 0.040 |
Why?
|
| Chemotactic Factors | 1 | 2020 | 197 | 0.040 |
Why?
|
| Conserved Sequence | 1 | 2002 | 1162 | 0.040 |
Why?
|
| Androgens | 1 | 2007 | 1285 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2011 | 9643 | 0.040 |
Why?
|
| Isotretinoin | 1 | 2020 | 134 | 0.040 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2009 | 3769 | 0.040 |
Why?
|
| Mathematical Concepts | 1 | 2019 | 73 | 0.040 |
Why?
|
| Laparoscopy | 1 | 2010 | 2030 | 0.040 |
Why?
|
| Joint Capsule | 1 | 2019 | 68 | 0.040 |
Why?
|
| Transcription Factor RelA | 1 | 2020 | 254 | 0.040 |
Why?
|
| Macrophages | 3 | 2013 | 5758 | 0.040 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2006 | 1932 | 0.040 |
Why?
|
| United States | 4 | 2021 | 72272 | 0.040 |
Why?
|
| Glucose Intolerance | 1 | 2003 | 575 | 0.040 |
Why?
|
| Alcohol Drinking | 3 | 2014 | 4025 | 0.040 |
Why?
|
| HeLa Cells | 3 | 2012 | 3087 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2002 | 2261 | 0.040 |
Why?
|
| Chemokines, CXC | 1 | 2020 | 416 | 0.040 |
Why?
|
| Adipokines | 2 | 2011 | 308 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2011 | 4745 | 0.040 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2019 | 183 | 0.040 |
Why?
|
| Mice, Transgenic | 4 | 2011 | 9529 | 0.040 |
Why?
|
| NF-kappa B | 2 | 2020 | 2481 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2013 | 5780 | 0.040 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2013 | 1914 | 0.040 |
Why?
|
| Viscera | 3 | 2003 | 138 | 0.040 |
Why?
|
| Gene Frequency | 3 | 2014 | 3601 | 0.040 |
Why?
|
| Vietnam | 1 | 2018 | 406 | 0.040 |
Why?
|
| Lysine | 1 | 2002 | 993 | 0.040 |
Why?
|
| Carbon Dioxide | 1 | 2002 | 1148 | 0.040 |
Why?
|
| Cell Movement | 1 | 2009 | 5200 | 0.040 |
Why?
|
| Scotland | 1 | 2017 | 143 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2012 | 5073 | 0.040 |
Why?
|
| Microcirculation | 1 | 2002 | 1272 | 0.040 |
Why?
|
| Health Priorities | 1 | 2020 | 375 | 0.040 |
Why?
|
| Italy | 1 | 2019 | 842 | 0.040 |
Why?
|
| Extracellular Matrix | 3 | 2010 | 1718 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2005 | 2112 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2008 | 3031 | 0.030 |
Why?
|
| Public Health | 2 | 2020 | 2669 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2018 | 671 | 0.030 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2003 | 831 | 0.030 |
Why?
|
| Virus Internalization | 1 | 2020 | 497 | 0.030 |
Why?
|
| Blood Proteins | 2 | 2013 | 1172 | 0.030 |
Why?
|
| Ethanol | 1 | 2003 | 1320 | 0.030 |
Why?
|
| Schizophrenia | 1 | 2015 | 6929 | 0.030 |
Why?
|
| Cattle | 2 | 2014 | 3841 | 0.030 |
Why?
|
| Cluster Analysis | 2 | 2014 | 2700 | 0.030 |
Why?
|
| Hospitalization | 4 | 2020 | 10704 | 0.030 |
Why?
|
| Spleen | 3 | 2011 | 2286 | 0.030 |
Why?
|
| Platelet Function Tests | 1 | 2018 | 271 | 0.030 |
Why?
|
| Organ Culture Techniques | 2 | 2010 | 794 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2004 | 1971 | 0.030 |
Why?
|
| Endosomes | 2 | 2012 | 522 | 0.030 |
Why?
|
| Platelet Membrane Glycoproteins | 2 | 2010 | 284 | 0.030 |
Why?
|
| Diabetic Nephropathies | 1 | 2003 | 972 | 0.030 |
Why?
|
| Resistance Training | 1 | 2018 | 193 | 0.030 |
Why?
|
| Rabbits | 1 | 2002 | 4770 | 0.030 |
Why?
|
| Models, Animal | 1 | 2002 | 2109 | 0.030 |
Why?
|
| Public Opinion | 1 | 2019 | 484 | 0.030 |
Why?
|
| Immunologic Memory | 2 | 2012 | 1355 | 0.030 |
Why?
|
| England | 1 | 2016 | 526 | 0.030 |
Why?
|
| Acne Vulgaris | 1 | 2020 | 349 | 0.030 |
Why?
|
| Arachidonic Acid | 1 | 2016 | 427 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2019 | 2864 | 0.030 |
Why?
|
| Arcus Senilis | 1 | 2014 | 4 | 0.030 |
Why?
|
| Gastrointestinal Agents | 1 | 2020 | 510 | 0.030 |
Why?
|
| Economics, Medical | 1 | 2015 | 112 | 0.030 |
Why?
|
| Calorimetry, Differential Scanning | 1 | 2014 | 100 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2019 | 1434 | 0.030 |
Why?
|
| Chromatography, Thin Layer | 1 | 2014 | 213 | 0.030 |
Why?
|
| Organizational Objectives | 1 | 2016 | 426 | 0.030 |
Why?
|
| Sympathetic Nervous System | 1 | 2017 | 519 | 0.030 |
Why?
|
| Vaccines | 1 | 2003 | 838 | 0.030 |
Why?
|
| User-Computer Interface | 1 | 2021 | 1397 | 0.030 |
Why?
|
| Hexuronic Acids | 1 | 2014 | 145 | 0.030 |
Why?
|
| Glucuronic Acid | 1 | 2014 | 150 | 0.030 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 1 | 2014 | 161 | 0.030 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2015 | 186 | 0.030 |
Why?
|
| Stromal Cells | 1 | 2020 | 1329 | 0.030 |
Why?
|
| Biological Assay | 1 | 2017 | 626 | 0.030 |
Why?
|
| Workflow | 1 | 2019 | 849 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2011 | 3730 | 0.030 |
Why?
|
| Drug Stability | 1 | 2014 | 291 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2019 | 1865 | 0.030 |
Why?
|
| Viscosity | 1 | 2014 | 336 | 0.030 |
Why?
|
| Diuretics | 1 | 2017 | 611 | 0.030 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 2 | 2008 | 244 | 0.030 |
Why?
|
| Lipogenesis | 1 | 2015 | 214 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2018 | 1217 | 0.030 |
Why?
|
| Glucosylceramidase | 1 | 2014 | 128 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2016 | 590 | 0.030 |
Why?
|
| Glycine | 1 | 2017 | 661 | 0.030 |
Why?
|
| Access to Information | 1 | 2016 | 316 | 0.030 |
Why?
|
| RNA Stability | 1 | 2015 | 320 | 0.030 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2014 | 274 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2016 | 587 | 0.030 |
Why?
|
| Software | 1 | 2007 | 4431 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2019 | 905 | 0.030 |
Why?
|
| Peptide Fragments | 2 | 2016 | 5110 | 0.030 |
Why?
|
| Transferases (Other Substituted Phosphate Groups) | 1 | 2013 | 36 | 0.030 |
Why?
|
| Phosphatidylglycerols | 1 | 2013 | 34 | 0.030 |
Why?
|
| Corynebacterium glutamicum | 1 | 2013 | 11 | 0.030 |
Why?
|
| Alginates | 1 | 2014 | 248 | 0.030 |
Why?
|
| Angina, Unstable | 1 | 2017 | 888 | 0.030 |
Why?
|
| Cardiolipins | 1 | 2013 | 81 | 0.030 |
Why?
|
| Adiposity | 2 | 2015 | 1879 | 0.030 |
Why?
|
| Office Visits | 1 | 2017 | 593 | 0.030 |
Why?
|
| Musculoskeletal Diseases | 1 | 2019 | 597 | 0.030 |
Why?
|
| Healthcare Disparities | 2 | 2018 | 3351 | 0.030 |
Why?
|
| Ventricular Function, Left | 1 | 2005 | 3873 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2015 | 876 | 0.030 |
Why?
|
| Body Fluids | 1 | 2014 | 320 | 0.030 |
Why?
|
| Canada | 1 | 2018 | 2118 | 0.030 |
Why?
|
| Rats | 2 | 2015 | 23717 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 2017 | 1335 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2006 | 6233 | 0.030 |
Why?
|
| Diffusion | 1 | 2014 | 814 | 0.030 |
Why?
|
| Renin-Angiotensin System | 1 | 2017 | 737 | 0.030 |
Why?
|
| Mass Spectrometry | 2 | 2014 | 2189 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2016 | 463 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2015 | 991 | 0.020 |
Why?
|
| Hybridomas | 1 | 2013 | 442 | 0.020 |
Why?
|
| Sphingomonas | 1 | 2011 | 6 | 0.020 |
Why?
|
| Transferrin | 1 | 2012 | 283 | 0.020 |
Why?
|
| Uric Acid | 1 | 2018 | 807 | 0.020 |
Why?
|
| Surface Properties | 1 | 2014 | 1161 | 0.020 |
Why?
|
| Mice, Knockout | 3 | 2013 | 14389 | 0.020 |
Why?
|
| Guinea Pigs | 2 | 2003 | 1310 | 0.020 |
Why?
|
| RNA Splice Sites | 1 | 2012 | 210 | 0.020 |
Why?
|
| Infant | 1 | 2013 | 36152 | 0.020 |
Why?
|
| Gene Duplication | 1 | 2012 | 314 | 0.020 |
Why?
|
| Marijuana Smoking | 1 | 2014 | 258 | 0.020 |
Why?
|
| Information Storage and Retrieval | 1 | 2016 | 819 | 0.020 |
Why?
|
| Autoimmunity | 1 | 2019 | 1350 | 0.020 |
Why?
|
| Psychometrics | 1 | 2021 | 3060 | 0.020 |
Why?
|
| Leukocytes | 1 | 2019 | 2023 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2014 | 943 | 0.020 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2012 | 250 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2013 | 411 | 0.020 |
Why?
|
| Lysosomes | 2 | 2009 | 924 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2012 | 489 | 0.020 |
Why?
|
| Genetic Heterogeneity | 1 | 2014 | 733 | 0.020 |
Why?
|
| Sleep | 1 | 2006 | 4758 | 0.020 |
Why?
|
| Systole | 2 | 2003 | 935 | 0.020 |
Why?
|
| Ligands | 2 | 2011 | 3268 | 0.020 |
Why?
|
| Netherlands | 1 | 2015 | 2221 | 0.020 |
Why?
|
| Receptors, Collagen | 1 | 2010 | 25 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2017 | 4570 | 0.020 |
Why?
|
| Organ Size | 1 | 2015 | 2252 | 0.020 |
Why?
|
| Mutant Chimeric Proteins | 1 | 2009 | 20 | 0.020 |
Why?
|
| Thinness | 1 | 2013 | 480 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 2456 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 1810 | 0.020 |
Why?
|
| Denmark | 1 | 2012 | 770 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2012 | 748 | 0.020 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2011 | 280 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2014 | 2495 | 0.020 |
Why?
|
| Nephelometry and Turbidimetry | 1 | 2009 | 91 | 0.020 |
Why?
|
| Introns | 1 | 2012 | 968 | 0.020 |
Why?
|
| Energy Intake | 2 | 2010 | 2132 | 0.020 |
Why?
|
| Toll-Like Receptors | 1 | 2013 | 575 | 0.020 |
Why?
|
| Protein Sorting Signals | 1 | 2010 | 278 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2015 | 2231 | 0.020 |
Why?
|
| Warfarin | 1 | 2018 | 1477 | 0.020 |
Why?
|
| Area Under Curve | 2 | 2003 | 1635 | 0.020 |
Why?
|
| Germinal Center | 1 | 2011 | 380 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2011 | 638 | 0.020 |
Why?
|
| Lipocalins | 1 | 2009 | 161 | 0.020 |
Why?
|
| Laboratories | 1 | 2012 | 458 | 0.020 |
Why?
|
| Thrombolytic Therapy | 1 | 2018 | 2055 | 0.020 |
Why?
|
| Genome | 1 | 2017 | 1737 | 0.020 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2011 | 544 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2019 | 5863 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 6474 | 0.020 |
Why?
|
| MADS Domain Proteins | 1 | 2008 | 19 | 0.020 |
Why?
|
| Life Expectancy | 1 | 2015 | 1239 | 0.020 |
Why?
|
| Body Weight | 3 | 2004 | 4614 | 0.020 |
Why?
|
| Cell Cycle Proteins | 2 | 2013 | 3447 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2012 | 1490 | 0.020 |
Why?
|
| Myogenic Regulatory Factors | 1 | 2008 | 102 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2019 | 2447 | 0.020 |
Why?
|
| Lipase | 1 | 2010 | 324 | 0.020 |
Why?
|
| Adaptive Immunity | 1 | 2012 | 724 | 0.020 |
Why?
|
| Temperature | 1 | 2014 | 2223 | 0.020 |
Why?
|
| Phosphatidylcholine-Sterol O-Acyltransferase | 1 | 2007 | 33 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2015 | 5034 | 0.020 |
Why?
|
| Glucose Transporter Type 4 | 1 | 2008 | 240 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2013 | 1134 | 0.020 |
Why?
|
| Indoles | 1 | 2015 | 1830 | 0.020 |
Why?
|
| Immunity, Humoral | 1 | 2011 | 600 | 0.020 |
Why?
|
| Fluorescence | 1 | 2010 | 756 | 0.020 |
Why?
|
| Counseling | 1 | 2015 | 1538 | 0.020 |
Why?
|
| Rural Population | 1 | 2018 | 2276 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2012 | 2063 | 0.020 |
Why?
|
| Antibodies | 1 | 2015 | 2414 | 0.020 |
Why?
|
| Computational Biology | 1 | 2019 | 3509 | 0.020 |
Why?
|
| Disease Models, Animal | 3 | 2017 | 18221 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2018 | 2745 | 0.020 |
Why?
|
| Isoelectric Focusing | 1 | 2006 | 150 | 0.020 |
Why?
|
| Metformin | 1 | 2014 | 906 | 0.020 |
Why?
|
| Gene Expression | 1 | 2019 | 7568 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2011 | 2214 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2012 | 1503 | 0.020 |
Why?
|
| Isoleucine | 1 | 2006 | 110 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2010 | 1540 | 0.020 |
Why?
|
| Interleukin-1 | 1 | 2010 | 1248 | 0.020 |
Why?
|
| Biological Availability | 1 | 2007 | 389 | 0.020 |
Why?
|
| Mortality | 1 | 2017 | 2899 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2012 | 3792 | 0.020 |
Why?
|
| Intestinal Absorption | 1 | 2007 | 400 | 0.020 |
Why?
|
| Streptococcus pneumoniae | 1 | 2011 | 730 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2020 | 20556 | 0.020 |
Why?
|
| Energy Transfer | 1 | 2005 | 108 | 0.020 |
Why?
|
| Dendritic Cells | 2 | 2009 | 2722 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2012 | 1742 | 0.020 |
Why?
|
| Weight Gain | 1 | 2015 | 2350 | 0.020 |
Why?
|
| Hormones, Ectopic | 1 | 2005 | 37 | 0.020 |
Why?
|
| Phosphatidylcholines | 1 | 2006 | 405 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2013 | 1963 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2010 | 36402 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2015 | 2978 | 0.020 |
Why?
|
| Founder Effect | 1 | 2005 | 185 | 0.020 |
Why?
|
| Anti-Obesity Agents | 1 | 2008 | 227 | 0.020 |
Why?
|
| Information Dissemination | 1 | 2013 | 1125 | 0.010 |
Why?
|
| Arthritis, Experimental | 1 | 2007 | 291 | 0.010 |
Why?
|
| Charcot-Marie-Tooth Disease | 1 | 2005 | 100 | 0.010 |
Why?
|
| Schwann Cells | 1 | 2005 | 197 | 0.010 |
Why?
|
| Abdominal Fat | 1 | 2006 | 221 | 0.010 |
Why?
|
| Peptides | 1 | 2016 | 4354 | 0.010 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2005 | 460 | 0.010 |
Why?
|
| Arthritis | 1 | 2010 | 680 | 0.010 |
Why?
|
| Resistin | 1 | 2005 | 172 | 0.010 |
Why?
|
| Binding Sites | 1 | 2013 | 6051 | 0.010 |
Why?
|
| Family | 1 | 2015 | 3193 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2010 | 1970 | 0.010 |
Why?
|
| Cell Lineage | 1 | 2012 | 2554 | 0.010 |
Why?
|
| Saponins | 1 | 2003 | 45 | 0.010 |
Why?
|
| Receptors, CCR3 | 1 | 2003 | 62 | 0.010 |
Why?
|
| COS Cells | 1 | 2005 | 1130 | 0.010 |
Why?
|
| Proteomics | 1 | 2017 | 3836 | 0.010 |
Why?
|
| Eosinophilia | 1 | 2008 | 559 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2012 | 3680 | 0.010 |
Why?
|
| Eosinophils | 1 | 2008 | 953 | 0.010 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2003 | 317 | 0.010 |
Why?
|
| Bradykinin | 1 | 2003 | 208 | 0.010 |
Why?
|
| Mycobacterium bovis | 1 | 2003 | 146 | 0.010 |
Why?
|
| Beer | 1 | 2003 | 134 | 0.010 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2003 | 202 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2011 | 3145 | 0.010 |
Why?
|
| Glycolipids | 1 | 2003 | 206 | 0.010 |
Why?
|
| Membrane Transport Proteins | 1 | 2008 | 1034 | 0.010 |
Why?
|
| Gene Library | 1 | 2005 | 1055 | 0.010 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2003 | 144 | 0.010 |
Why?
|
| Liver Transplantation | 1 | 2014 | 2329 | 0.010 |
Why?
|
| Ultrasonography, Doppler, Pulsed | 1 | 2002 | 19 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2002 | 412 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 2003 | 696 | 0.010 |
Why?
|
| Selectins | 1 | 2002 | 101 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2008 | 1594 | 0.010 |
Why?
|
| Health Surveys | 1 | 2012 | 4037 | 0.010 |
Why?
|
| Motor Activity | 1 | 2012 | 2714 | 0.010 |
Why?
|
| Chromatography, Gas | 1 | 2002 | 151 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2005 | 1989 | 0.010 |
Why?
|
| Plant Oils | 1 | 2002 | 198 | 0.010 |
Why?
|
| Colorimetry | 1 | 2002 | 150 | 0.010 |
Why?
|
| Sciatic Nerve | 1 | 2005 | 618 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2021 | 12661 | 0.010 |
Why?
|
| Observer Variation | 1 | 2007 | 2606 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2002 | 767 | 0.010 |
Why?
|
| Lymphoid Tissue | 1 | 2002 | 445 | 0.010 |
Why?
|
| Pregnancy Complications | 1 | 2015 | 2948 | 0.010 |
Why?
|
| Granuloma | 1 | 2003 | 328 | 0.010 |
Why?
|
| Sampling Studies | 1 | 2002 | 615 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 5430 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 14591 | 0.010 |
Why?
|
| Health Status Disparities | 1 | 2012 | 1846 | 0.010 |
Why?
|
| Immunohistochemistry | 2 | 2005 | 11069 | 0.010 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2002 | 304 | 0.010 |
Why?
|
| Administration, Inhalation | 1 | 2003 | 1156 | 0.010 |
Why?
|
| Genome, Human | 1 | 2012 | 4421 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2002 | 927 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 2002 | 1433 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2010 | 2688 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2013 | 3842 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2013 | 7583 | 0.010 |
Why?
|
| Femoral Artery | 1 | 2003 | 826 | 0.010 |
Why?
|
| Species Specificity | 1 | 2002 | 2411 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 2002 | 1597 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2005 | 2639 | 0.010 |
Why?
|
| Adjuvants, Immunologic | 1 | 2003 | 990 | 0.010 |
Why?
|
| Lasers | 1 | 2002 | 952 | 0.010 |
Why?
|
| Apoptosis | 1 | 2014 | 9476 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2002 | 1964 | 0.010 |
Why?
|
| Cell Separation | 1 | 2002 | 1718 | 0.010 |
Why?
|
| Leptin | 1 | 2005 | 1595 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2003 | 2358 | 0.010 |
Why?
|
| Exons | 1 | 2002 | 2381 | 0.010 |
Why?
|
| Syndrome | 1 | 2002 | 3268 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2005 | 3431 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2012 | 11514 | 0.010 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2005 | 2872 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2002 | 2661 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 2002 | 1389 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2002 | 6188 | 0.010 |
Why?
|
| Pregnancy | 1 | 2015 | 29868 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2002 | 3998 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2008 | 9586 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2003 | 6346 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2002 | 8998 | 0.000 |
Why?
|
| Lung | 1 | 2003 | 9998 | 0.000 |
Why?
|